Infliximab

Hospital use only.

Remicade (reference infliximab product), Remsima and Inflectra (biosimilars) are available.

NICE TA329: for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. (Decision date - March 2015)
NICE TA373: for treating juvenile idiopathic arthritis (Decision date - March 2015)
NICE TA375: for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. (Decision date - February 2016)
NICE TA383: for ankylosing spondylitis and non-radiographic axial spondyloarthritis. (Decision date - March 2016)
NICE TA715: Adalimumab, etanercept and infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. (Decision date - August 2021)
SSC2596: for refractory sarcoidosis (excluding neurosarcoidosis). NHSE commissioned. (Decision date - April 2024)

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)